semaglutide od FDA Clears For Cardiac Risk Reduction in Diabetic Patients FDA alerts health care providers,

Role of the gut microbiota and its metabolites in tumorigenesis or development of colorectal cancer

The loss of STAT3 proteins caused the nuclear exclusion of FoxO proteins

A direct quantitative comparison between disulfide- and diselenide-linked carriers remains limited in the literature, hindering accurate assessment of structurefunction relationships

Early clinical trials have shown promising results in terms of weight reduction, glycemic control, and improvements in liver health, positioning Survodutide as a potential next-generation therapy for patients with obesity, type 2 diabetes, and nonalcoholic steatohepatitis (NASH)